Veterans Affairs declines to cover Biogen’s Alzheimer’s drug over effectiveness, safety concerns

Stat News

11 August 2021 - The Department of Veterans Affairs has decided not to cover a new Alzheimer’s drug from Biogen, citing insufficient evidence of “a robust and meaningful clinical benefit” and concerns about safety.

In a notice issued by the agency, the Department said it will make exceptions for “highly selected patients” and listed several hurdles that must be cleared before the medicine will be covered, such as requiring it to be prescribed by providers who specialise in treating dementia and ensuring patients had recently received MRI brain scans.

Read Stat News article

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Medicine , US , Market access , Veterans